Neurol. praxi. 2011;12(5):307-310

Treatment of delirium

doc.MUDr.Ján Pečeňák, CSc.
Psychiatrická klinika LF UK a UNB, Bratislava

Delirium is a universal pathological reaction of brain to different noxious factors. The treatment is complex and often complicated. It

must start early and to be oriented both to the primary factor (disease) and to the symptoms of delirium. The most often used drugs in the

treatment of delirium are antipsychotics, particularly haloperidol and tiapride. Atypical antipsychotics are used with consideration of their

pharmacological profiles. Risperidone and olanzapine are mostly used for this indication. Benzodiazepines should not be systematically

applied for treatment of delirium, except in the case of alcohol dependence and delirium with seizures. Short-acting benzodiazepines

are suitable for temporary treatment in the need for sedation. There are not enough data for other drugs like drugs used for dementia

and nootropics. Results from studies with small number of patients or case reports are only available.

Keywords: delirium, treatment, antipsychotics, benzodiazepines

Published: November 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pečeňák J. Treatment of delirium. Neurol. praxi. 2011;12(5):307-310.
Download citation

References

  1. Attard A, Ranjith G, Taylor D. Delirium and its treatment. CNS Drugs.2008; 22(8): 631-644. Go to original source... Go to PubMed...
  2. Bourne RS, Tahir TA, Borthwick M, Sampson EL. Drug treatment of delirium: past, present and future. J Psychosom Res. 2008 Sep; 65(3): 273-282. Go to original source... Go to PubMed...
  3. Campbell N, Boustani MA, Ayub A, Fox GC, Munger SL, Ott C, Guzman O, Farber M, Ademuyiwa A, Singh R. Pharmacological management of delirium in hospitalized adults-a systematic evidence review. J Gen Intern Med. 2009; 24(7): 848-853. Go to original source... Go to PubMed...
  4. Clinical Practice Guidelines for the Management of Delirium in Older People. Melbourne: Victorian Government Department of Human Services 2006; 103s.
  5. Čaplová T. Poruchy vedomia. In. Kolibáš E, a kol. Všeobecná psychiatria. Bratislava, Univerzita Komenského, 2007; 92-97s.
  6. Devlin JW, Skrobik Y. Antipsychotics for the prevention and treatment of delirium in the intensive care unit: what is their role? Harv Rev Psychiatry. 2011; 19(2): 59-67. Go to original source... Go to PubMed...
  7. Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol. 2009; 5(4): 210-220. Go to original source... Go to PubMed...
  8. Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics. 2004; 45(4): 297-301. Go to original source... Go to PubMed...
  9. Jirák R. Deliria - závažný a nedoceněný problém gerontopsychiatrie. Psychiatr. prax. 2005; 6(2): 74-77.
  10. Konrád J. Deliria (stavy zmatenosti) u geriatrických pacientů. Čes Ger Rev 2006; 4(2): 65-71.
  11. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010; 70(3): 287-312. Go to original source... Go to PubMed...
  12. Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4): 8-16. Go to original source... Go to PubMed...
  13. Miller MO. Evaluation and management of delirium in hospitalized older patients. Am Fam Physician. 2008; 78(11): 1265-1270. Go to PubMed...
  14. MKCH 10. Medzinárodná štatistická klasifikácia chorôb a príbuzných zdravotných problémov 10. revízia. 1. diel. Ústav zdravotníckych informácií a štatistiky. Obzor, 1994; 821s.
  15. Molčan J, Vinař O, Přibyl R, Kolibáš E, Čaplová T, Heretik A. K možnostiam použitia nootropných látok v klinickej psychiatrii. Čs. Psychiat. 1978; 74(2): 52-60.
  16. NICE. DELIRIUM: diagnosis, prevention and management. Draft. 2010. http://guidance.nice.org.uk/nicemedia/live/11874/48522/48522.pdf.
  17. Oldenbeuving AW, de Kort PL, Jansen BP, Kappelle LJ, Roks G. A pilot study of rivastigmine in the treatment of delirium after stroke: a safe alternative. BMC Neurol. 2008; 20: 8-34. Go to original source... Go to PubMed...
  18. Praško J, Bartoš A. Kvalitativní poruchy vědomí. In: Bartoš A a kol. Diagnostika poruch vědomí v klinické praxi. Praha, Karolinum, 2004; s167-199.
  19. Rais AR, Williams K, Rais T, Singh T, Tamburrino M. Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study. Psychiatry (Edgmont). 2010; 7(1): 17-24.
  20. Seitz DP, Gill SS, van Zyl LT. Antipsychotics in the treatment of delirium: a systematic review. J Clin Psychiatry. 2007; 68(1): 11-21. Go to original source... Go to PubMed...
  21. Schwartz TL, Masand PS. Treatment of Delirium With Quetiapine. Prim Care Companion J Clin Psychiatry. 2000; 2 (1): 10-12. Go to original source... Go to PubMed...
  22. Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006; 35(4): 350-364. Go to original source... Go to PubMed...
  23. Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. Psychosomatics. 1998; 39(5): 422-430. Go to original source... Go to PubMed...
  24. Straker DA, Shapiro PA, Muskin PR. Aripiprazole in the treatment of delirium. Psychosomatics. 2006; 47(5): 385-391. Go to original source... Go to PubMed...
  25. Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad B. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord. 2002; 13(4): 217-224. * Informácie o liekoch - indikáciách a dávkach - sú spracované podľa platných SPC (Summary of Product Characteristics = Súhrn charakteristických vlastností lieku) zverejnených na www. sukl.sk alebo www.sukl.cz (prístup marec - apríl 2001). Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.